Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus Type 2 With Hyperglycemia Clear all
Completed Phase 4 Interventional Results available

Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery

NCT00596687
View directory record Official record
Conditions
Type 2 Diabetes, Inpatient Hyperglycemia
Interventions
Insulin glargine, Regular insulin, Insulin glulisine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 1 Interventional

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

NCT04373265
View directory record Official record
Conditions
Adrenocortical Carcinoma
Interventions
Relacorilant, Pembrolizumab
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
6
States / cities
Stanford, California • Tampa, Florida • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00763451
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Blood Pressure Medications on Metabolism

NCT00642434
View directory record Official record
Conditions
Diabetes
Interventions
carvedilol, metoprolol
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
45 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 2 Interventional Results available

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

NCT00995930
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 4 Interventional

Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes

NCT00394407
View directory record Official record
Conditions
Diabetes, Hyperglycemia
Interventions
sliding scale regular insulin, glargine basal insulin and glulisine prandial insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 1, 2026, 9:29 PM EDT
Recruiting Not applicable Interventional

Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes

NCT06735651
View directory record Official record
Conditions
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Female, Adult, Endothelial Function (Reactive Hyperemia), Arterial Stiffness, Cognition, Oxidative Stress, Gut Microbiota, Overweight, Inflammation, Microvascular Function, Body Composition
Interventions
Wild Blueberry, Placebo
Dietary Supplement
Lead sponsor
Georgia State University
Other
Eligibility
20 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 1, 2026, 9:29 PM EDT
Withdrawn Phase 3 Interventional

A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus

NCT02106364
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Peglispro, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Zephyrhills, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 4 Interventional Results available

Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Diabetes

NCT00590226
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Detemir + aspart insulin before meals, NPH insulin + regular insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

NCT01719003
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hyperglycemia
Interventions
Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd, Empagliflozin high dose qd, Empagliflozin low dose bid, Empagliflozin high dose bid
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
41
States / cities
Birmingham, Alabama • Manley Hot Springs, Alaska • Glendale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 1, 2026, 9:29 PM EDT
Terminated Not applicable Interventional

Hyperglycemia and Oxidative Stress in the Human Brain With Diabetes

NCT00775541
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Vitamin C
Dietary Supplement
Lead sponsor
In-Young Choi, Ph.D.
Other
Eligibility
30 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Oct 1, 2026, 9:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Health Effects of Liposuction in Overweight Women With Elevated Insulin Levels, Impaired Glucose Tolerance and/or Type 2 Diabetes

NCT00005760
View directory record Official record
Conditions
Glucose Intolerance, Hyperinsulinemia, Diabetes Mellitus, Non Insulin Dependent, Obesity
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 1, 2026, 9:29 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)

NCT05874635
View directory record Official record
Conditions
Weight Loss, Metabolic Syndrome, Diabetes Mellitus, Type 2, Central Obesity, Insulin Resistance, Glucose Intolerance, Metabolic Glucose Disorders
Interventions
Continuous Glucose Monitor Device
Device
Lead sponsor
Signos Inc
Industry
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 1, 2026, 9:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Not applicable Interventional Results available

CTSI Pilot: Improving Adherence to Diabetic Diet

NCT04051008
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diet, Healthy, Pre-diabetes
Interventions
Online - use of online grocery shopping platform, Default - use of online grocery shopping platform with default shopping carts
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 1, 2026, 9:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Colesevelam HCl On Bile Acid Kinetics

NCT00476710
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Colesevelam HCl
Drug
Lead sponsor
KineMed
Industry
Eligibility
40 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Early Phase 1 Interventional

Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients

NCT02012465
View directory record Official record
Conditions
Lymphoma, Diabetes Mellitus, Type 2, Hyperglycemia
Interventions
Insulin protocol
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00712673
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Not applicable Interventional Results available

Time in Glucose Hospital Target

NCT05135676
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Blinded CGM, real-time CGM
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 4 Interventional Results available

Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)

NCT00979628
View directory record Official record
Conditions
Type 2 Diabetes, Hyperglycemia
Interventions
sliding scale regular insulin (SSRI), Basal Bolus, Basal Plus
Drug
Lead sponsor
Guillermo Umpierrez, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Atlanta, Georgia • Decatur, Georgia • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone

NCT00763815
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Pioglitazone, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

NCT00328627
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Alogliptin, Alogliptin placebo, Pioglitazone, Pioglitazone placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
72
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

NCT01845831
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Sitagliptin, Basal Bolus, Metformin and Sitagliptin, Glargine, Glargine 50%, Glargine 80%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 1, 2026, 9:29 PM EDT